Company Description
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD.
It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.
Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Joshua Disbrow |
Contact Details
Address: Denver Corporate Center III, Suite 920 Denver, Colorado 80237 United States | |
| Phone | 720 437 6580 |
| Website | aytubio.com |
Stock Details
| Ticker Symbol | AYTU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001385818 |
| CUSIP Number | 054754874 |
| ISIN Number | US0547548588 |
| Employer ID | 47-0883144 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua R. Disbrow | Chief Executive Officer and Director |
| Ryan J. Selhorn CPA | Chief Financial Officer, Corporate Secretary and Treasurer |
| Jarrett T. Disbrow Ph.D. | Chief Business Officer |
| Greg Pyszczymuka | Chief Commercial Officer |
| Margaret Cabano | Vice President of Operations |
| Dr. Gerwin Westfield Ph.D. | Senior Vice President of Scientific Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | SCHEDULE 13G/A | Filing |
| Oct 24, 2025 | ARS | Filing |
| Oct 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 24, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 23, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 23, 2025 | 10-K | Annual Report |
| Sep 23, 2025 | 8-K | Current Report |